Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Timo, Marttila"'
Autor:
Terho Lehtimäki, Antti Rannikko, Mikkel Fode, Michael Borre, Teuvo Tammela, Aino Siltari, Peter Østergren, Mika Helminen, Timo Marttila, Otto Ettala, Heikki Seikkula, Peter Boström, Jarno Riikonen, Juha Koskimäki, Tomi Pakarainen, Andres Kotsar, Paavo V Raittinen, Arto Salonen, Hanna Ronkainen, Sven Löffeler, Teemu J Murtola
Publikováno v:
BMJ Open, Vol 12, Iss 4 (2022)
Introduction Blood cholesterol is likely a risk factor for prostate cancer prognosis and use of statins is associated with lowered risk of prostate cancer recurrence and progression. Furthermore, use of statins has been associated with prolonged time
Externí odkaz:
https://doaj.org/article/e505fd6f8e7d4cd2a0760857e0947b59
Autor:
Aino Siltari, Jarno Riikonen, Juha Koskimäki, Tomi Pakarainen, Otto Ettala, Peter Boström, Heikki Seikkula, Andres Kotsar, Teuvo Tammela, Mika Helminen, Paavo V Raittinen, Terho Lehtimäki, Mikkel Fode, Peter Østergren, Michael Borre, Antti Rannikko, Timo Marttila, Arto Salonen, Hanna Ronkainen, Sven Löffeler, Teemu J Murtola
Publikováno v:
Siltari, A, Riikonen, J, Koskimäki, J, Pakarainen, T, Ettala, O, Boström, P, Seikkula, H, Kotsar, A, Tammela, T, Helminen, M, Raittinen, P V, Lehtimäki, T, Fode, M, Østergren, P, Borre, M, Rannikko, A, Marttila, T, Salonen, A, Ronkainen, H, Löffeler, S & Murtola, T J 2022, ' Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy : study protocol ', BMJ Open, vol. 12, no. 4, e050264 . https://doi.org/10.1136/bmjopen-2021-050264
IntroductionBlood cholesterol is likely a risk factor for prostate cancer prognosis and use of statins is associated with lowered risk of prostate cancer recurrence and progression. Furthermore, use of statins has been associated with prolonged time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4944b012a4cd842994136075a1e269c
http://hdl.handle.net/10138/344338
http://hdl.handle.net/10138/344338
Autor:
Miikka Lehtonen, Jorma Sormunen, Tiina Luukkaala, Timo Marttila, Ray McDermott, Timo Joensuu, Ilari Lehtinen, Claes Ginman, Pirkko-Liisa Kellokumpu-Lehtinen
Introduction: Treatment with 2-weekly docetaxel 50 mg/m2 was shown to improve overall survival and was better tolerated than the standard 75 mg/m2 3-weekly regimen in men with metastatic castration-resistant prostate cancer (mCRPC) in the original ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::122cbeb4f20ed8b0403fb5ff04a84700
https://trepo.tuni.fi/handle/10024/141440
https://trepo.tuni.fi/handle/10024/141440
Autor:
Ville Sell, Otto Ettala, Ileana Montoya Perez, Riikka Järvinen, Tarmo Pekkarinen, Markku Vaarala, Marjo Seppänen, Tapani Liukkonen, Timo Marttila, Sirpa Aaltomaa, Peter J. Boström
Publikováno v:
European urology focus. 8(5)
Data regarding patient education and smoking habits among bladder cancer patients are scarce.To investigate awareness of smoking as a risk factor for bladder cancer among bladder cancer patients.This is a substudy of a prospective, randomized, multic
Autor:
Eero Kaasinen, Marjo Seppänen, Timo Marttila, Markku H. Vaarala, Ville Sell, Tarmo Pekkarinen, Ileana Montoya Perez, Riikka Järvinen, Peter J. Boström, Otto Ettala, Sirpa Aaltomaa, Tapani Liukkonen
Publikováno v:
World Journal of Urology
Purpose To investigate the symptoms and delays in the clinical pathway of bladder cancer (BC). Methods This is a substudy of a prospective, randomized, multicenter phase III study (FinnBladder 9, NCT01675219) where the efficacy of photodynamic diagno
Autor:
Petteri Hervonen, Antti Jekunen, Timo Marttila, Teppo Huttunen, Vesa Kataja, Marjaana Luukkaa, Pirkko-Liisa Kellokumpu-Lehtinen, Tapio Utriainen, Katariina Klintrup, Kalevi Pulkkanen, Anna-Liisa Kautio, Markku J Leskinen
Publikováno v:
Anticancer research. 40(12)
Background/Aim: Our phase III trial showed that biweekly docetaxel (D) is better tolerated than triweekly D in metastatic castration-resistant prostate cancer (mCRPC). The safety of biweekly cabazitaxel (CBZ) post-docetaxel was studied in mCRPC. Pati
Autor:
Lasse Levomäki, Antti Salminen, Taina Isotalo, Peter J. Boström, Otto Ettala, Christian Palmberg, Jouko Viitanen, Jukka Sairanen, Mikael Anttinen, Tapani Liukkonen, Ilmari Koskinen, Saija Hurme, Marjo Seppänen, Timo Marttila, Markku H. Vaarala, Juhani Ottelin, Timo K. Nykopp, Ileana Montoya Perez, Matti Säily, Teemu J. Murtola, Sebastian Becker, Dimitri Pogodin-Hannolainen
Publikováno v:
European Urology Oncology. 1(6):525-530
Background Neoadjuvant chemotherapy (NAC) is underutilized in the treatment of bladder cancer (BC). Objective To investigate the effect of NAC on the risk of surgical complications for radical cystectomy (RC) in a population-based setting. Design, se
Autor:
Mika Raitanen, Tapani Liukkonen, Erkki Rintala, Timo Marttila, Teuvo L.J. Tammela, Riikka Järvinen, Marjo Seppänen, Peter J. Boström, Pekka Hellström, Sirpa Aaltomaa, Markku J Leskinen, Eero Kaasinen
Publikováno v:
European Urology. 70:341-347
Background Patients with non–muscle-invasive bladder cancer (NMIBC) belonging to the intermediate-risk group should be treated with intravesical instillations to prevent recurrence and progression. Objective We compared the outcome of a monthly mai
Autor:
Eero Kaasinen, Timo Marttila, Jukka Kallio, Jouko Viitanen, Markku H. Vaarala, Sirpa Aaltomaa, Kari Tuhkanen, Tapani Liukkonen, Veli-Matti Puolakka, Peter J. Boström, Riikka Järvinen, Erkki Rintala, Marjo Seppänen
Publikováno v:
European Urology. 68(4):611-617
Background Recurrent TaT1 non–muscle-invasive bladder cancer (NMIBC) patients should be treated with immediate instillation of chemotherapy after transurethral resection of bladder tumour followed by instillation therapy. Objective To present long-
Autor:
S. Becker, Tapani Liukkonen, I. Montoya Perez, Taina Isotalo, Timo Marttila, Jouko Viitanen, Ilmari Koskinen, Markku H. Vaarala, Saija Hurme, D. Pogodin-Hannolainen, Marjo Seppänen, L. Levomäki, Mikael Anttinen, Teemu J. Murtola, J. Ottelin, Peter J. Boström, Otto Ettala, Christian Palmberg, Antti Salminen, Matti Säily, Jukka Sairanen, Timo K. Nykopp
Publikováno v:
European Urology Supplements. 17:e1033-e1034